These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22890011)

  • 1. Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibrate.
    Frazier-Wood AC; Aslibekyan S; Borecki IB; Hopkins PN; Lai CQ; Ordovas JM; Straka RJ; Tiwari HK; Arnett DK
    Pharmacogenet Genomics; 2012 Oct; 22(10):750-7. PubMed ID: 22890011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment.
    Smith JA; Arnett DK; Kelly RJ; Ordovas JM; Sun YV; Hopkins PN; Hixson JE; Straka RJ; Peacock JM; Kardia SL
    Eur J Hum Genet; 2008 May; 16(5):603-13. PubMed ID: 18212815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variants associated with VLDL, LDL and HDL particle size differ with race/ethnicity.
    Frazier-Wood AC; Manichaikul A; Aslibekyan S; Borecki IB; Goff DC; Hopkins PN; Lai CQ; Ordovas JM; Post WS; Rich SS; Sale MM; Siscovick D; Straka RJ; Tiwari HK; Tsai MY; Rotter JI; Arnett DK
    Hum Genet; 2013 Apr; 132(4):405-13. PubMed ID: 23263444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary evidence of genetic determinants of adiponectin response to fenofibrate in the Genetics of Lipid Lowering Drugs and Diet Network.
    Aslibekyan S; An P; Frazier-Wood AC; Kabagambe EK; Irvin MR; Straka RJ; Tiwari HK; Tsai MY; Hopkins PN; Borecki IB; Ordovas JM; Arnett DK
    Nutr Metab Cardiovasc Dis; 2013 Oct; 23(10):987-94. PubMed ID: 23149075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network.
    Aslibekyan S; Kabagambe EK; Irvin MR; Straka RJ; Borecki IB; Tiwari HK; Tsai MY; Hopkins PN; Shen J; Lai CQ; Ordovas JM; Arnett DK
    Pharmacogenet Genomics; 2012 Mar; 22(3):191-7. PubMed ID: 22228203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein lipase S447X variant associated with VLDL, LDL and HDL diameter clustering in the MetS.
    Wood AC; Glasser S; Garvey WT; Kabagambe EK; Borecki IB; Tiwari HK; Tsai MY; Hopkins PN; Ordovas JM; Arnett DK
    Lipids Health Dis; 2011 Aug; 10():143. PubMed ID: 21854610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network.
    Tsai MY; Ordovas JM; Li N; Straka RJ; Hanson NQ; Arends VL; Arnett D
    Mol Genet Metab; 2010 Jun; 100(2):118-22. PubMed ID: 20346718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common CD36 SNPs reduce protein expression and may contribute to a protective atherogenic profile.
    Love-Gregory L; Sherva R; Schappe T; Qi JS; McCrea J; Klein S; Connelly MA; Abumrad NA
    Hum Mol Genet; 2011 Jan; 20(1):193-201. PubMed ID: 20935172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate.
    Aslibekyan S; Goodarzi MO; Frazier-Wood AC; Yan X; Irvin MR; Kim E; Tiwari HK; Guo X; Straka RJ; Taylor KD; Tsai MY; Hopkins PN; Korenman SG; Borecki IB; Chen YD; Ordovas JM; Rotter JI; Arnett DK
    PLoS One; 2012; 7(10):e48663. PubMed ID: 23119086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of fenofibrate on insulin sensitivity and plasma lipid profile in non-diabetic males with low high density lipoprotein/dyslipidaemic syndrome.
    Yong QW; Thavintharan S; Cheng A; Chew LS
    Ann Acad Med Singap; 1999 Nov; 28(6):778-82. PubMed ID: 10672386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels.
    Phuntuwate W; Suthisisang C; Koanantakul B; Chaloeiphap P; Mackness B; Mackness M
    Atherosclerosis; 2008 Jan; 196(1):122-128. PubMed ID: 17412348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of CYP7A1 polymorphisms on lipid responses to fenofibrate.
    Shen J; Arnett DK; Parnell LD; Lai CQ; Straka RJ; Hopkins PN; An P; Feitosa MF; Ordovás JM
    J Cardiovasc Pharmacol; 2012 Mar; 59(3):254-9. PubMed ID: 22075751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study.
    Liu Y; Ordovas JM; Gao G; Province M; Straka RJ; Tsai MY; Lai CQ; Zhang K; Borecki I; Hixson JE; Allison DB; Arnett DK
    Pharmacogenet Genomics; 2009 Feb; 19(2):161-9. PubMed ID: 19057464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease.
    Fabbrini E; Mohammed BS; Korenblat KM; Magkos F; McCrea J; Patterson BW; Klein S
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2727-35. PubMed ID: 20371660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study.
    Ikewaki K; Tohyama J; Nakata Y; Wakikawa T; Kido T; Mochizuki S
    J Atheroscler Thromb; 2004; 11(5):278-85. PubMed ID: 15557710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.
    Genest J; Nguyen NH; Theroux P; Davignon J; Cohn JS
    J Cardiovasc Pharmacol; 2000 Jan; 35(1):164-72. PubMed ID: 10630748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic risk scores associated with baseline lipoprotein subfraction concentrations do not associate with their responses to fenofibrate.
    Frazier-Wood AC; Wojczynski MK; Borecki IB; Hopkins PN; Lai CQ; Ordovas JM; Straka RJ; Tsai MY; Tiwari HK; Arnett DK
    Biology (Basel); 2014 Aug; 3(3):536-50. PubMed ID: 25157911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.